Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Measuring Psoriasis Severity at Home02:28

Measuring Psoriasis Severity at Home

776
This paper details the creation of a Psoriasis Thickness Reference Card, enabling psoriasis patients to self-assess their psoriasis plaque thickness without the need for physician assistance. Additionally, the precision of self-assessment for psoriasis redness and scaliness by employing reference images depicting various skin tones is...
776
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

39.4K
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The Goeckerman regimen, formulated for the treatment of psoriasis, consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). The following protocol is for the administration of Goeckerman therapy for the treatment of moderate-to-severe...
39.4K
Generalized Hooke's Law01:22

Generalized Hooke's Law

2.6K
The generalized Hooke's Law is a broadened version of Hooke's Law, which extends to all types of stress and in every direction. Consider an isotropic material shaped into a cube subjected to multiaxial loading. In this scenario, normal stresses are exerted along the three coordinate axes. As a result of these stresses, the cubic shape deforms into a rectangular parallelepiped. Despite this deformation, the new shape maintains equal sides, and there is a normal strain in the direction of the...
2.6K
Generalized Anxiety Disorder01:30

Generalized Anxiety Disorder

649
Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry that persists for at least six months, significantly interfering with daily functioning. Unlike situational anxiety, which arises in response to specific stressors, GAD often occurs without a clear cause. Individuals may experience disproportionate worry about work, health, or relationships. For instance, a person might continuously fear poor health despite normal medical evaluations or...
649
Social Foundations of Self II: The Generalized Other01:20

Social Foundations of Self II: The Generalized Other

234
According to George Herbert Mead, as children progress beyond the game stage, they develop a more comprehensive understanding of societal rules and norms. This cognitive and social development enables them to internalize the expectations of the broader community, refining their ability to regulate behavior.Consistent participation in organized activities is crucial in helping children recognize that their actions are not isolated but contribute to a more significant, interconnected group...
234
Generalization, Discrimination, and Extinction01:24

Generalization, Discrimination, and Extinction

1.4K
Generalization, discrimination, and extinction are key concepts in operant conditioning that influence how behaviors are learned and maintained.
Generalization occurs when a behavior reinforced in one context is performed in similar situations. For instance, a student who studies diligently for calculus and receives excellent grades might apply the same study habits to psychology and history, expecting similar results. Generalization shows how learning in one setting can influence behavior in...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RE: Comment on ''The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial''.

Journal of the American Academy of Dermatology·2026
Same author

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

The Journal of dermatology·2026
Same author

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Journal of the American Academy of Dermatology·2026
Same journal

Mast cell activation disorders: mechanisms, comorbidities and look alike.

Expert review of clinical immunology·2026
Same journal

Dendritic cell subsets in alopecia areata: focus on plasmacytoid dendritic cells and Langerhans cells in immune imbalance and therapeutic implications.

Expert review of clinical immunology·2026
Same journal

The role of immunosenescence and chronic medical conditions on the immune response to respiratory syncytial virus in older individuals.

Expert review of clinical immunology·2026
Same journal

Flow cytometry-based basophil and mast cell activation tests for IgE-mediated food and drug allergy: have we crossed the Rubicon?

Expert review of clinical immunology·2026
Same journal

An update on the pharmacotherapy of ANCA-associated vasculitis.

Expert review of clinical immunology·2026
Same journal

Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.

Expert review of clinical immunology·2026
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

776

An update on generalized pustular psoriasis.

Melinda J Gooderham1, Abby S Van Voorhees2, Mark G Lebwohl3

  • 1SKiN Centre for Dermatology, Probity Medical Research, Queen's University , Peterborough , ON , Canada.

Expert Review of Clinical Immunology
|September 6, 2019
PubMed
Summary
This summary is machine-generated.

Generalized pustular psoriasis (GPP) is a distinct disease requiring new treatments. Targeting the interleukin-36 (IL-36) pathway shows promise for managing this severe condition.

Keywords:
BiologicsGPPIL-36IL-36 receptor antagonistgeneralized pustular psoriasisvon Zumbusch

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K
Generalized Hooke's Law
01:22

Generalized Hooke's Law

2.6K

Related Experiment Videos

Last Updated: Jan 20, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

776
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K
Generalized Hooke's Law
01:22

Generalized Hooke's Law

2.6K

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Generalized pustular psoriasis (GPP) is a severe, multisystem disease distinct from plaque psoriasis.
  • The interleukin-36 (IL-36) pathway is implicated in GPP pathogenesis.
  • Current GPP treatments are limited, with no approved agents in the US or Europe.

Purpose of the Study:

  • To review current literature on GPP genetics, pathogenesis, and treatment.
  • To highlight the potential of anti-IL-36 therapies for GPP management.

Main Methods:

  • Literature search of PubMed and Google Scholar for articles on GPP, psoriasis, genetics, pathogenesis, and treatment.

Main Results:

  • GPP is a distinct entity requiring specific diagnostic and therapeutic approaches.
  • The IL-36 pathway is a key target for GPP treatment.
  • Early data suggest novel anti-IL-36 therapies are effective and safe.

Conclusions:

  • New therapeutic options and guidelines are needed for GPP.
  • Anti-IL-36 therapies represent a promising avenue for GPP management.
  • Development of scoring systems and objective outcome measures is crucial for evaluating new therapies.